Citadel Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-400
| Closed | -$2.14K | – | 12477 |
|
|
2025
Q1 | $2.14K | Buy |
400
+300
| +300% | +$2.1K | ﹤0.01% | 14062 |
|
|
2024
Q4 | $894 | Sell |
100
-5,600
| -98% | -$59.5K | ﹤0.01% | 14257 |
|
|
2024
Q3 | $62.8K | Sell |
5,700
-5,800
| -50% | -$64.5K | ﹤0.01% | 11658 |
|
|
2024
Q2 | $105K | Sell |
11,500
-141,300
| -92% | -$1.38M | ﹤0.01% | 10848 |
|
|
2024
Q1 | $2.15M | Buy |
152,800
+132,000
| +635% | +$1.64M | ﹤0.01% | 5379 |
|
|
2023
Q4 | $160K | Buy |
20,800
+12,600
| +154% | +$69.7K | ﹤0.01% | 10287 |
|
|
2023
Q3 | $61.2K | Buy |
8,200
+1,700
| +26% | +$14.5K | ﹤0.01% | 11505 |
|
|
2023
Q2 | $54.1K | Buy |
6,500
+1,900
| +41% | +$21.9K | ﹤0.01% | 11704 |
|
|
2023
Q1 | $61.2K | Sell |
4,600
-3,400
| -43% | -$46K | ﹤0.01% | 11903 |
|
|
2022
Q4 | $119K | Buy |
+8,000
| New | +$82.5K | ﹤0.01% | 10977 |
|
|
2022
Q3 | – | Sell |
-77,900
| Closed | -$234K | – | 12572 |
|
|
2022
Q2 | $234K | Sell |
77,900
-111,200
| -59% | -$499K | ﹤0.01% | 10356 |
|
|
2022
Q1 | $1.27M | Sell |
189,100
-62,776
| -25% | -$374K | ﹤0.01% | 7151 |
|
|
2021
Q4 | $1.36M | Buy |
+251,876
| New | +$1.66M | ﹤0.01% | 7126 |
|
|
2021
Q3 | – | Sell |
-8,617
| Closed | -$109K | – | 13773 |
|
|
2021
Q2 | $109K | Buy |
8,617
+6,600
| +327% | +$85.7K | ﹤0.01% | 12841 |
|
|
2021
Q1 | $35K | Sell |
2,017
-3,833
| -66% | -$69.2K | ﹤0.01% | 13004 |
|
|
2020
Q4 | $75K | Buy |
5,850
+2,300
| +65% | +$41K | ﹤0.01% | 10378 |
|
|
2020
Q3 | $132K | Buy |
+3,550
| New | +$141K | ﹤0.01% | 9091 |
|
Citadel Advisors's ATXS Position: Q1 2026 in Review
Citadel Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 113,555 shares — an estimated $1.49M sold.
Citadel Advisors first reported a position in ATXS in Q1 2017 and held it in 25 quarters. The position peaked at $12.9M in Q2 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Citadel Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 113,555 Astria Therapeutics shares in Q1 2026, an estimated $1.49M.
- Citadel Advisors first reported a position in Astria Therapeutics in Q1 2017 and held it in 25 quarters.
- Citadel Advisors's Astria Therapeutics position peaked at $12.9M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.